Accelerate to discover
Related topics
Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice
Dec 28, 2020
Radio-active sources have been used routinely for the preconditioning in humanized mouse models, but safety issues have...
EV imaging series: Using ONI super-resolution to characterize single-EVs
Dec 23, 2020
To date, researchers commonly use flow-based characterization methods, fluorescence imaging techniques and electron...
Don’t Let Waste Anesthetic Gases Harm You!
Dec 21, 2020
Many projects have been devoted to the study of the correlation between anesthetics and Alzheimer’s disease....
Advances in Leukemia research using shear flow and Bioflux system
Dec 10, 2020
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
Dosimetric characterization of an X-ray irradiator for use with cells
Dec 4, 2020
This study aims to characterize an X-ray irradiator for use with cells using its internal parallel-plate ionization...
Modeling multiple myeloma-Bone Marrow interactions using Synthecon rotating-wall vessels
Dec 2, 2020
Multiple myeloma develops primarily inside the bone marrow microenvironment, that confers pro-survival signals and drug...
Bruker webinar: Ear evolution in fossil mammals
Nov 27, 2020
Hearing is just one of the functions aside of providing balance. Even juveniles obtain a fully developed ear region...
ONI Nanoimager joins the fight against COVID-19
Nov 24, 2020
ONI is supporting the global effort into research and diagnostics to tackle the COVID-19 pandemic. ONI is currently...
Jan 11, 2019
CAR T-cell therapy and bispecific antibodies are two approaches that have addressed the targeting of more than one epitope, the redirecting of T lymphocytes to kill tumor cells, and the improvement of efficacy in solid tumor types. For a closer look at the design, development, and success of CAR T-cell therapy and bispecific antibodies, a panel of experts come together to discuss their research and share insights into the potential these therapeutics hold in the fight against various tumor types.
Learning objectives:
-Molecular mechanism of PD-L1 regulation in cancer cells
-Immunosuppressive nature of triple negative breast cancer
-Using in vitro co-culture system to analyze T cell-mediated cancer cell killing effect
-Complete the form below to access this webinar recording.
Bruce Levine, PhD, Abramson Cancer Center, University of Pennsylvania
Related technologies: Automated microscopy and image analysis
Get more info
Brand profile
Essen BioScience (part of Sartorius), is a team of engineers and biologists with deep expertise in cell-based assays. They invent, manufacture, supply and support cell-based assay instrumentation, reagents and protocols.
More info at:
essenbioscience.com/en/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
